Clinical Trials Logo

Herpangina clinical trials

View clinical trials related to Herpangina.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03266601 Completed - Herpangina Clinical Trials

Effect of Recombinant Human Interferon α-2b Spray on Herpangina

Start date: June 1, 2016
Phase: Phase 4
Study type: Interventional

This is a multicenter, open,randomized controlled trial aiming to evaluate the effectiveness of recombinant human interferon α-2b spray compared with ribavirin treatment on pediatric patients with herpangina.

NCT ID: NCT03241030 Completed - Clinical trials for Hand, Foot and Mouth Disease

Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial

Start date: September 12, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if sucralfate, a medication commonly used for patients with stomach ulcers, may help pediatric patients with mouth ulcers decrease their pain level and improve their ability to drink.

NCT ID: NCT01508247 Completed - Clinical trials for Hand, Foot and Mouth Disease

A Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months

Start date: January 2012
Phase: Phase 3
Study type: Interventional

Since its discovery in 1969, enterovirus 71 (EV71) has been recognised as a frequent cause of epidemics of hand-foot-mouth disease (HFMD) associated with severe neurological sequelae in a small proportion of cases. There has been a significant increase in EV71 epidemic activity throughout the Asia-Pacific region since 1997. Recent HFMD epidemics in this region have heen associated with a severe from of brainstem encephalitis associated with pulmonary oedema and high case-fatality rates. The data from the phase 1 and 2 trials suggested that the inactivated EV71 vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese children and infants. According to the immunogenicity and safety results, the 320U with adjuvant with immunizing schedule of two doses (per 28 day) will be applied in phase 3 clinical trial.